Newsroom

News

Antibiotics are a double-edged sword – they should be as toxic as possible to pathogenic bacteria while being harmless to the cells of the human body. An international research team led by the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) has now developed drug candidates that achieve precisely that. The new molecules target a metabolic pathway that only occurs in bacterial cells, thus sparing human cells. The team published its results in the journal Angewandte Chemie International Edition.

13.01.2025

HIPS

Atomic model of Bacteroides thetaiotaomicron RbpB protein with individual B. thetaiotaomicron bacteria in the background

News

Researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) and the Julius-Maximilians-Universität (JMU) in Würzburg have identified a protein and a group of small ribonucleic acids (sRNAs) in Bacteroides thetaiotaomicron, which regulate sugar metabolism. These discoveries shed light on how this gut microbe adapts to varying nutritional conditions. The findings deepen our understanding of this bacterium's role in the human gut and may pave the way for new therapeutic strategies to promote health through the microbiota. The study was published in the journal Nature Communications.

09.01.2025

HIRI

News

Researchers at the Helmholtz Centre for Infection Research (HZI) have developed a promising new vaccine technology. Their studies to date show that just one dose of vaccine leads to effective and long-lasting immune protection. The basis of this so-called MCMV vaccine vector technology is the mouse cytomegalovirus (MCMV). It acts as a carrier virus that introduces selected antigens of a pathogen to be vaccinated against into the body. In the follow-up project VIVA-VEK-2, which was launched at the HZI at the beginning of January, a proof-of-concept vaccine candidate against respiratory syncytial virus (RSV) is now to be produced and tested for efficacy and tolerability. The researchers believe that with the new vaccine technology, one vaccine dose could possibly even provide lifelong protection. The project is funded by the GO-Bio initial program of the Federal Ministry of Education and Research (BMBF) over two years with a funding volume of one million euros.

07.01.2025

HZI Campus

HIPS

The Horizon Europe project DEFENDER is exploring new targets for antiviral therapies

News

The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with around eight 9.6 million euros as part of Horizon Europe. Almost 700,000 euros of these will go to Prof. Mark Brönstrup, a researcher at the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF).

06.01.2025

HZI Campus

News

A research team from the Helmholtz Institute for One Health (HIOH) has investigated the distribution and characteristics of multidrug-resistant bacteria in the Baltic Sea. The findings prove that resistant pathogens occur not only in samples taken from clinical settings but also from the environment. The BMBF-funded study also underlines the importance of an integrated strategy for combatting multidrug resistance that takes equal account of environmental and health protection. The results were published recently in the scientific journal npj Clean Water.

23.12.2024

HIOH

Scanning electron micrograph of Mycobacterium tuberculosis

News

Global migration has increased in recent decades due to war, conflict, persecutions, and natural disasters, but also secondary to increased opportunities related to work or study. A group of international experts that collaborate in the Tuberculosis Network European Trialsgroup (TBnet), led by Heinke Kunst from Queen Mary College of London, Berit Lange from the Epidemiology Department at the Helmholtz Centre for Infection Research (HZI), Christoph Lange from the Research Center Borstel and Anca Vasiliu from Baylor College of Medicine, has now identified the risk for tuberculosis and comorbidities in migrants to the European Union/European Economic Area and the United Kingdom (EU/EEA/&UK).

19.12.2024

HZI Campus

Back to the first page
...
27
28
29
30
...
151

HZI in the media

are extremely complex.

Researchers at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) have now shown that artificial

21.10.2026

Phys.org

Würzburg (JMU) und dem Helmholtz-Institut für RNA-basierte Infektionsforschung (HIRI), einem Standort des HZI in ...

20.10.2026

Regional Heute

community. HIPS is a site of the Helmholtz Centre for Infection Research (HZI) that operates in collaboration with Saarland University.

20.10.2026

WDC Tv News

... Verabreichung eintritt. Expertin Berit Lange vom Helmholtz-Zentrum für Infektionsforschung betonte, dass jetzt der richtige Moment ...

16.10.2026

upday

... Berit Lange im Gespräch mit FOCUS online. Sie ist Leiterin der Abteilung Epidemiologie am Helmholtz-Zentrum ...

16.10.2026

Focus Online

protection against BV. Researchers from the Helmholtz Centre for Infection Research have reported evidence that antibodies produced after

16.10.2026

Medscape

... ist Leiterin der Abteilung Epidemiologie am Helmholtz-Zentrum für Infektionsforschung in Braunschweig und Mitglied der Ständigen ...

16.10.2026

Berliner Morgenpost

... beeindruckendes Ergebnis“, sagt Jakob Wirbel vom Helmholtz-Zentrum für Infektionsforschung (HZI). „Trotzdem schlafe ich momentan noch ...

15.10.2026

Der Tagesspiegel

... Lange, Leiterin der Abteilung Epidemiologie am Helmholtz-Zentrum für Infektionsforschung in Braunschweig und Mitglied der Ständigen ...

14.10.2026

DIE WELT

also included Japanese microbiologists and collaborators from IST Austria and HZI Braunschweig (Germany), demonstrated that actin inhibitors

14.10.2026

Health Medicine Network

... in der Abteilung „Virale Immunologie“ am Helmholtz-Zentrum für Infektionsforschung (HZI), hat die WHO als externer ...

13.10.2026

DeutschesGesundheitsPortal

tool called Metax, developed by researchers at the Helmholtz Centre for Infection Research (HZI) in Braunschweig and described in the

12.10.2026

Bioengineer.org

Register now for the HZI newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.